341O Safety and efficacy of zoldonrasib (RMC-9805) plus daraxonrasib (RMC-6236) in patients with 2L+ KRAS G12D metastatic pancreatic adenocarcinoma (mPDAC)
作者
N.S. Azad,D G Kim,Paul E. Oberstein,Brian A. Mannion,M. Pelster,K. Ng,R. Yaeger,E.J-H. Kim,K.P. Papadopoulos,Patricia Mucci LoRusso,J.D. Powderly,A Parikh,J.S. Wang,D. Orr,Maria Filippou-Frye,H. Patel,Satwant Lally,W. Yu,A. Spira,D.S. Hong